135 related articles for article (PubMed ID: 20845257)
1. [Pharmacological vitreolysis].
Gandorfer A
Klin Monbl Augenheilkd; 2011 Mar; 228(3):201-7. PubMed ID: 20845257
[TBL] [Abstract][Full Text] [Related]
2. Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy.
Costa Ede P; Rodrigues EB; Farah ME; Sebag J; Meyer CH
Curr Pharm Biotechnol; 2011 Mar; 12(3):410-22. PubMed ID: 20939794
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic vitreolysis.
Gandorfer A
Dev Ophthalmol; 2007; 39():149-156. PubMed ID: 17245084
[TBL] [Abstract][Full Text] [Related]
4. Novel possibility of vitreomacular traction treatment.
Michalska-Małecka K; Witek K; Sierocka-Stępień J; Wyględowska-Promieńska D; Nowak M
Acta Ophthalmol; 2016 Dec; 94(8):e818-e819. PubMed ID: 27167161
[No Abstract] [Full Text] [Related]
5. Experimental evaluation of microplasmin - an alternative to vital dyes.
Gandorfer A
Dev Ophthalmol; 2008; 42():153-159. PubMed ID: 18535388
[TBL] [Abstract][Full Text] [Related]
6. Ocriplasmin: nonsurgical option for VMA and macular hole, but with potential barriers to practical use.
Ober MD; Hariprasad SM
Ophthalmic Surg Lasers Imaging Retina; 2013; 44(2):113-6; discussion p.113. PubMed ID: 23510035
[No Abstract] [Full Text] [Related]
7. Safety and complications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe art thou?
Kim JE
JAMA Ophthalmol; 2014 Apr; 132(4):379-80. PubMed ID: 24577332
[No Abstract] [Full Text] [Related]
8. [Progression of pharmacologic vitreolysis research].
Zhou H; Ye J
Zhonghua Yan Ke Za Zhi; 2014 Mar; 50(3):225-9. PubMed ID: 24841819
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological vitrectomy.
Tanaka M; Qui H
Semin Ophthalmol; 2000 Mar; 15(1):51-61. PubMed ID: 10749315
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy and Safety Profile of Ocriplasmin in Vitreomacular Interface Disorders.
Shaikh M; Miller JB; Papakostas TD; Husain D
Semin Ophthalmol; 2017; 32(1):52-55. PubMed ID: 27786583
[TBL] [Abstract][Full Text] [Related]
11. Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when?
Ziemssen F; Bartz-Schmidt KU; Dimopoulos S
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):615-6. PubMed ID: 26887826
[No Abstract] [Full Text] [Related]
12. Objective of pharmacologic vitreolysis.
Gandorfer A
Dev Ophthalmol; 2009; 44():1-6. PubMed ID: 19494646
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic vitreolysis--premise and promise of the first decade.
Sebag J
Retina; 2009; 29(7):871-4. PubMed ID: 19584647
[No Abstract] [Full Text] [Related]
14. [The need for pharmacology in vitreoretinal surgery SOE Lecture 2007].
Gandorfer A
Klin Monbl Augenheilkd; 2007 Dec; 224(12):900-4. PubMed ID: 18260053
[TBL] [Abstract][Full Text] [Related]
15. Ocriplasmin for symptomatic vitreomacular adhesion.
Blue Cross and Blue Shield Association
Technol Eval Cent Assess Program Exec Summ; 2013 Aug; 28(5):1-3. PubMed ID: 24066370
[No Abstract] [Full Text] [Related]
16. Enzymatic Vitrectomy and Pharmacologic Vitreodynamics.
Shah AR; Trese MT
Dev Ophthalmol; 2016; 55():357-64. PubMed ID: 26501959
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic Vitreolysis in Vascular Diseases of the Retina.
Soliman MK; Agarwal A; Sarwar S; Hanout M; Sadiq MA; Do DV; Nguyen QD
Ophthalmic Surg Lasers Imaging Retina; 2016 Jan; 47(1):60-8. PubMed ID: 26731211
[TBL] [Abstract][Full Text] [Related]
18. Plasmin-assisted vitrectomy eliminates cortical vitreous remnants.
Gandorfer A; Ulbig M; Kampik A
Eye (Lond); 2002 Jan; 16(1):95-7. PubMed ID: 11913902
[No Abstract] [Full Text] [Related]
19. Correspondence.
Primavera V; Querques G
Retina; 2014 Dec; 34(12):e39-40. PubMed ID: 25407235
[No Abstract] [Full Text] [Related]
20. Reply: To PMID 23881226.
Stalmans P; Duker JS
Retina; 2015 Apr; 35(4):e28-9. PubMed ID: 25807179
[No Abstract] [Full Text] [Related]
[Next] [New Search]
